Holen Sie sich die Stockscreener-App
11.27
2.45%
0.27
Handel nachbörslich:
11.46
0.19
+1.69%
Mink Therapeutics Inc Aktie (INKT) Neueste Nachrichten
MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript - Sahm
H.C. Wainwright Maintains MiNK Therapeutics(INKT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
MiNK Therapeutics (NASDAQ:INKT) Stock Rating Lowered by Zacks Research - MarketBeat
MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript - AOL.com
MiNK Therapeutics (NASDAQ:INKT) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
MiNK Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
MiNK Therapeutics, Inc. (INKT) Presents at 2026 Military Health System Research SymposiumSlideshow - Seeking Alpha
MiNK Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
META_TITLE_QUOTE - Yahoo Finance
MiNK Therapeutics Q2 Earnings Call Highlights - MarketBeat
MiNK Therapeutics Q2 Results: Net loss narrows to $3.1M, cash at $8.8M - scanx.trade
INKT: Advanced phase II ARDS trial and global access for agenT-797, with stable financials - TradingView
MiNK Therapeutics (INKT.US) will release its earnings report after market close on August 13. - 富途牛牛
Earnings call transcript: MiNK Therapeutics narrows Q2 2026 loss as trial advances - Investing.com
Transcript : MiNK Therapeutics, Inc., Q2 2026 Earnings Call, Aug 13, 2026 - marketscreener.com
INKT: Phase II trial for agenT-797 in ARDS shows early promise; global access and financial discipline maintained - TradingView
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury - Investing News Network
Form 8K Mink Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
MiNK Therapeutics reports Phase 2 trial data for agenT-797 By Investing.com - Investing.com Australia
MiNK Therapeutics reports Phase 2 trial data for agenT-797 - Investing.com
MiNK Reports $3.1 Million Second-Quarter Loss and Phase 2 ARDS Update - Quiver Quantitative
MiNK Therapeutics Q2 loss narrows on expense discipline - TradingView
Mink Therapeutics Inc (INKT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mink Therapeutics Inc expected to post a loss of 60 cents a shareEarnings Preview - TradingView
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates - Investing News Network
MiNK Therapeutics, Inc. (INKT) Stock: Climbs on Encouraging Phase 2 Data for agenT-797 in Severe Pneumonia - Blockonomi
Transactions récentes par des initiés de Mink Therapeutics Inc. R (6Q40.F) - Yahoo Finance France
MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium - GlobeNewswire
Liquidity Mapping Around (INKT) Price Events - Stock Traders Daily
MiNK Therapeutics to Report Second Quarter 2026 Financial Results and Provide Corporate Update on agenT-797 Clinical Progress - Quiver Quantitative
MiNK Therapeutics to Report Second Quarter 2026 Financial - GlobeNewswire
New agenT-797 lung-injury data due from MiNK Aug. 13 - Stock Titan
MiNK Therapeutics (INKT) Projected to Post Earnings on Thursday - MarketBeat
Mink Therapeutics to report Q2 results, host conference call and webcast - Bitget
INKT Q2'26 Earnings: revenue estimate is 0 USD - TradingView
MiNK Therapeutics (INKT) Climbs 5.7% as Biotech Momentum BuildsStraddle Setup - dars.gov.et
MiNK Therapeutics Q1 2026 Earnings: Narrower Loss than Expected Reflects Cost DisciplineQuarterly Earnings - dars.gov.et
Mink Therapeutics Inc (INKT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mink Therapeutics Inc (INKT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mink Therapeutics Inc (INKT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
Mink Therapeutics Inc (INKT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
INKT|Mink Therapeutics Inc|Price:11.070|Chg%:+0.700 - TradingKey
TradingKey - TradingKey
Mink Therapeutics Inc (INKT) Balance Sheet - TradingKey
Mink Therapeutics Inc (INKT) Income Statement - TradingKey
MiNK Therapeutics, Inc. Revenue Breakdown – FWB:6Q40 - TradingView
Mink Therapeutics Inc (INKT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mink Therapeutics Inc (INKT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MiNK Therapeutics, Inc. Revenue Breakdown – MUN:6Q40 - TradingView
INKT|Mink Therapeutics Inc|Price:10.600|Chg%:-0.470 - TradingKey
INKT|Mink Therapeutics Inc|Price:11.310|Chg%:+0.620 - TradingKey
INKT|Mink Therapeutics Inc|Price:11.380|Chg%:+0.310 - TradingKey
Mink Therapeutics Inc (INKT) Institutional Confidence - TradingKey
MiNK Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost ManagementEBITDA Analysis - dars.gov.et
Here's why you should add INKT stock to your portfolio now - MSN
MiNK Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SurpriseEarnings Whisper Number - dars.gov.et
Here's Why You Should Add INKT Stock to Your Portfolio Now - TradingView
What date does MiNK Therapeutics, Inc.'s (INKT) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Why (INKT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Mink Therapeutics (INKT) Proxy filing Summary - Quartr
Mink Therapeutics (INKT) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary - Quartr
Mink Therapeutics (INKT) Q1 2025 earnings summary - Quartr
Cost of goods sold of MiNK Therapeutics, Inc. – DUS:6Q40 - TradingView
Understanding Momentum Shifts in (INKT) - Stock Traders Daily
MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Value Benchmark Index - marketscreener.com
MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Growth Benchmark Index - marketscreener.com
MiNK Therapeutics, Inc.(NasdaqCM: INKT) added to Russell 3000E Growth Benchmark - marketscreener.com
MiNK Therapeutics, Inc.(NasdaqCM: INKT) added to Russell Microcap Index - marketscreener.com
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):